Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
March 10, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, March 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology
March 03, 2022 07:00 ET
|
Autolus Therapeutics plc
- Publication describing a novel technology that provides for very low levels of expression of one programming module relative to another programming module1 - Method for expressing stable low levels...
Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10
February 21, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces retirement of chief financial officer and succession plan
January 10, 2022 07:01 ET
|
Autolus Therapeutics plc
- Andrew J. Oakley to retire in March 2022 - Dr. Lucinda Crabtree to succeed him as chief financial officer LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a...
Autolus Therapeutics announces 2022 priorities
January 10, 2022 07:00 ET
|
Autolus Therapeutics plc
- obe-cel has the potential to transform outcomes for adult ALL patients - Phase 2 FELIX study data expected in 2022 LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq:...
Autolus Therapeutics to Present at Conferences During January 2022
January 05, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition
December 13, 2021 07:00 ET
|
Autolus Therapeutics plc
- Obe-cel shows sustained durability of response with morphological EFS of 46% at 24 months in the ALLCAR19 study - Obe-cel response and safety data from the Phase 1b portion of the FELIX study...
Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition
December 06, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
November 15, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells
November 10, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...